| EQUITY BASED PAYMENTS |
NOTE
9 – EQUITY BASED PAYMENTS
The
Company accounts for equity-based payment accruals under authoritative guidance as set forth in the Topics of the ASC. The guidance requires
all equity-based payments to employees and non-employees, including grants of employee and non-employee stock options and warrants, to
be recognized in the consolidated financial statements based at their fair values.
Stock
Incentive Plans
The
Company has the following stock incentive plans:
Effective
January 15, 2020, the Company adopted its 2020 Stock Option and Award Plan (the “2020 Stock Incentive Plan”). A total of
2,222 shares of the Company’s common stock were reserved for the 2020 Stock Incentive Plan. As of March 31, 2025 and December 31,
2024, there were no grants made under the 2020 Stock Incentive Plan. On May 4, 2023, the Company terminated the 2020 Stock Incentive
Plan.
Effective
August 9, 2022, the Company adopted its 2022 Incentive and Non-statutory Stock Option Plan (the “2022 Stock Option Plan”).
Under the 2022 Stock Option Plan, the Board of Directors may grant options to purchase common stock to officers, employees, and other
persons who provide services to the Company. A total of 833,333 shares of the Company’s common stock is reserved for the 2022 Stock
Option Plan.
The
Company granted and issued the following stock options during the nine months ended September 30, 2025:
| |
○ |
The
Company granted and issued 708,333 shares of common stock under the 2022 Stock Option Plan to its employees during the three months
ended September 30, 2025. Under the stock option grant, these shares were fully vested at the time of issuance with no exercise price.
The common stock share trading price was $0.52 per share at the time of issuances and the Company recognized $365,641 as stock compensation
expense during the nine months ended March 31, 2025. No compensation expense related to these shares were recognized during the three
months ended September 30, 2025. |
The
Company did not have any stock options outstanding as of September 30, 2025 as the previously issued stock options were immediately vested,
exercised, and issued.
Effective
August 9, 2022, the Company adopted its 2022 Restricted Stock Plan (the “2022 Restricted Stock Plan”). Under the 2022 Restricted
Stock Plan, the Board of Directors may grant restricted stock to officers, directors, and key employees. A total of 833,333 shares of
common stock is reserved for the 2022 Restricted Stock Plan.
The
Company granted and issued the following restricted stock during the nine months ended September 30, 2025:
| |
○ |
The
Company granted and issued 833,333 shares of common stock under the 2022 Restricted Stock Plan to its employees during the nine months
ended September 30, 2025. Under the plan, these shares were fully vested at the time of issuance with no exercise price. The common
stock share trading price was $0.52 per share at the time of issuances and the Company recognized $430,166 as stock compensation
expense during the nine months ended September 30, 2025 and none during the three months ended September 30, 2025. |
The
Company did not have any restricted stock options outstanding as of September 30, 2025 as the previously issued stock options were immediately
vested, exercised, and issued.
Stock
Compensation - Others
At
time to time, the Company issues common stock to its Board of Directors, outside service providers or consultants.
The
Company had the following common stock issuances during the nine months ended September 30, 2025:
| |
● |
Issuances
of Shares for Accrued Board of Directors Compensation Settlement – The Company issued 1,945,000 common stock shares
to its Board of Directors for prior year services of which the Company had accrued $972,500 as accrued board compensation at December
31, 2024. The accrued amount of $972,500 was settled with issuance of 1,945,000 common shares. As a result, the Company recorded
a loss on debt settlement of $680,750 based on fair value during the nine months ended September 30, 2025. |
| |
● |
Issuances
of Shares for Board of Directors Compensation – The Company issued 220,000 common stock shares to its Board of Directors
for its services. The common stock share trading price was $1.00 per share at the time of issuance and the Company recognized $220,000
as stock compensation expense during the three months ended March 31, 2025 and none during the three months ended September 30, 2025. |
| |
● |
Issuances
of Shares to Consultants for Services – The Company issued 578,757 common stock shares to consultants. Some of these
consultants require entire year of 2025 services, therefore, some of stock compensation expense of $403,518 was recorded as prepaid
at March 31, 2025. The prepaid amount was $58,073 at March 31, 2025 and is recorded as prepaid expenses in the consolidated balance
sheets and none during the three months ended September 30, 2025. |
| |
|
|
| |
● |
Issuances
of Shares for Conversion of Vendor Debt – The Company issued 739,002 common stock shares to settle vendor debt valued
at $739,002 during three months ended September 30, 2025. |
| |
● |
Issuances
of Shares to Consultants for Services – On June 12, 2025, the Company entered into a consulting agreement with a consultant
whereby the Company will issue 600,000, restricted shares as a consulting fee of the Company’s common stock to the consultant
to be delivered over 12 months as follows: 200,000 shares to be delivered to the Company’s transfer agent in the Consultant’s
name upon signing the contract. 400,000 restricted, Company, common shares to be delivered over 12 months as follows: Earned and
vested monthly starting at the end of month 4 through 11 in 44,444 equal share increments. In month twelve, 44,448 shares shall be
earned and vested. The Company expensed common shares pro-ratably over the service period and recorded stock compensation expense
of $136,183 for shares vested and issued of 222,220 shares for the nine months ended September 30, 2025 and $0 for shares vested
and issuable of 44,448 as of September 30, 2025 and for the nine months ended September 30, 2025. The Company issued 133,332 shares
from shares issuable from December 31, 2024 during the nine months ended September 30, 2025. |
| |
● |
Issuances
of Shares for Accrued Salaries Settlement – The Company issued 1,340,598 common stock shares to its employees for prior
year accrued wages of $536,251. The accrued amount of $536,251 was settled with issuance of 1,340,598 common shares. As a result,
the Company recorded a loss on debt settlement of $589,989 based on fair value during the nine months ended September 30, 2025. |
| |
● |
Common
Stock and Preferred D Shares Issuable from Additional Borrowings from Notes Payable to Shareholder ($500,000) – On
March 21, 2025, the Company entered into a Loan Authorization and Agreement for a loan of $500,000 from a shareholder, the proceeds
of which were to be used for working capital purposes. The loan has an interest rate of 12.5% per annum and is due within 6 months
from the date of the agreement. Furthermore, the Company is required to issue 10,000 preferred C shares (issued on April 10, 2025)
and 225,000 common stock shares (issued on April 10, 2025) under the agreement. These shares were calculated at fair value at the
date of issuance and the Company recorded interest expense of $427,750. The $500,000 was converted to preferred stock C during the
nine months ended September 30, 2025. |
| |
|
|
| |
● |
Issuances
of Shares for Accrued Salaries Settlement – On September 30, 2025, the Company entered into a settlement agreement
with its employees by converting accrued salaries of $1,266,670
for the period from January 1, 2025 to June 30, 2025 to common shares at a price of $1.21
per share which resulted in common stock issuable of 1,046,836.
The fair value of the common share price was $2.20
at the date of the settlement, which resulted a loss on settlement of debt in the amount of $1,036,369
for the nine months ended September 30, 2025.
|
| |
|
|
| |
● |
Issuances of Common Shares for Related Party Loan Payable – In
July 2025, the Company issued 520,000 common shares for related party loan inducement with the fair value at $334,092. |
| |
|
|
| |
● |
Issuances of Common Shares from Common Share Issuable - During the nine
months ended September 30, 2025, the Company issued 133,332 common shares in the amount of $83,555 from common share payable. |
| |
|
|
| |
● |
Common Share Issuable of 44,448 valued at $20,070
– During the nine months ended September 30, 2025, the Company recorded 44,448 as common share issuable valued at $20,070 for
consulting services. |
| |
|
|
| |
● |
Common Shares Issued for Consulting Services – During the
nine months ended September 30, 2025, the Company issued 100,000 common shares for consulting services valued at $399,000. |
|